BIOLASE, Inc. Logo

BIOLASE, Inc.

BIOL

(0.8)
Stock Price

0,02 USD

-69.27% ROA

12267.09% ROE

-0.03x PER

Market Cap.

731.942,00 USD

-338.28% DER

0% Yield

-41.65% NPM

BIOLASE, Inc. Stock Analysis

BIOLASE, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BIOLASE, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.09x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-338.32%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-78.91%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The company has a high debt to equity ratio (219%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-1), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

BIOLASE, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BIOLASE, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BIOLASE, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BIOLASE, Inc. Revenue
Year Revenue Growth
1992 5.500.000
1993 2.400.000 -129.17%
1994 1.100.000 -118.18%
1995 1.200.000 8.33%
1996 700.000 -71.43%
1997 1.800.000 61.11%
1998 1.500.000 -20%
1999 7.004.272 78.58%
2000 9.657.389 27.47%
2001 17.887.000 46.01%
2002 29.199.000 38.74%
2003 49.081.000 40.51%
2004 60.651.000 19.08%
2005 61.980.000 2.14%
2006 69.700.000 11.08%
2007 66.889.000 -4.2%
2008 64.625.000 -3.5%
2009 43.347.000 -49.09%
2010 26.225.000 -65.29%
2011 48.858.000 46.32%
2012 57.356.000 14.82%
2013 56.430.000 -1.64%
2014 47.656.000 -18.41%
2015 48.475.000 1.69%
2016 51.810.000 6.44%
2017 46.926.000 -10.41%
2018 46.155.000 -1.67%
2019 37.799.000 -22.11%
2020 22.780.000 -65.93%
2021 39.188.000 41.87%
2022 48.462.000 19.14%
2023 43.684.000 -10.94%
2023 49.164.000 11.15%
2024 46.220.000 -6.37%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BIOLASE, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 900.000 100%
1996 1.000.000 10%
1997 1.000.000 0%
1998 1.800.000 44.44%
1999 2.427.510 25.85%
2000 2.287.503 -6.12%
2001 1.520.000 -50.49%
2002 1.684.000 9.74%
2003 2.505.000 32.77%
2004 3.576.000 29.95%
2005 6.306.000 43.29%
2006 4.876.000 -29.33%
2007 5.104.000 4.47%
2008 5.580.000 8.53%
2009 4.146.000 -34.59%
2010 3.790.000 -9.39%
2011 4.311.000 12.09%
2012 4.684.000 7.96%
2013 4.029.000 -16.26%
2014 4.577.000 11.97%
2015 7.283.000 37.16%
2016 7.799.000 6.62%
2017 6.229.000 -25.2%
2018 5.203.000 -19.72%
2019 4.765.000 -9.19%
2020 3.695.000 -28.96%
2021 6.048.000 38.91%
2022 7.265.000 16.75%
2023 5.448.000 -33.35%
2023 6.004.000 9.26%
2024 4.284.000 -40.15%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BIOLASE, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 7.400.000
1993 7.000.000 -5.71%
1994 3.800.000 -84.21%
1995 1.400.000 -171.43%
1996 1.600.000 12.5%
1997 2.200.000 27.27%
1998 3.400.000 35.29%
1999 5.173.172 34.28%
2000 6.174.296 16.21%
2001 9.432.000 34.54%
2002 13.932.000 32.3%
2003 21.681.000 35.74%
2004 34.632.000 37.4%
2005 41.560.000 16.67%
2006 36.109.000 -15.1%
2007 37.589.000 3.94%
2008 12.006.000 -213.09%
2009 7.835.000 -53.24%
2010 6.557.000 -19.49%
2011 7.936.000 17.38%
2012 8.075.000 1.72%
2013 9.377.000 13.89%
2014 14.854.000 36.87%
2015 10.256.000 -44.83%
2016 10.453.000 1.88%
2017 9.712.000 -7.63%
2018 11.771.000 17.49%
2019 10.748.000 -9.52%
2020 9.772.000 -9.99%
2021 11.258.000 13.2%
2022 12.309.000 8.54%
2023 10.716.000 -14.87%
2023 10.216.000 -4.89%
2024 12.256.000 16.64%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BIOLASE, Inc. EBITDA
Year EBITDA Growth
1992 -5.300.000
1993 -6.900.000 23.19%
1994 -3.900.000 -76.92%
1995 -1.700.000 -129.41%
1996 -2.400.000 29.17%
1997 -3.000.000 20%
1998 -10.200.000 70.59%
1999 -4.680.430 -117.93%
2000 -3.467.542 -34.98%
2001 -278.000 -1147.32%
2002 2.461.000 111.3%
2003 7.512.000 67.24%
2004 -1.680.000 547.14%
2005 -15.320.000 89.03%
2006 -2.446.000 -526.33%
2007 -7.627.000 67.93%
2008 -4.937.000 -54.49%
2009 -2.960.000 -66.79%
2010 -10.387.000 71.5%
2011 -3.309.000 -213.9%
2012 -2.531.000 -30.74%
2013 -10.996.000 76.98%
2014 -17.941.000 38.71%
2015 -21.118.000 15.04%
2016 -13.582.000 -55.49%
2017 -16.388.000 17.12%
2018 -17.255.000 5.02%
2019 -14.639.000 -17.87%
2020 -13.822.000 -5.91%
2021 -15.716.000 12.05%
2022 -24.841.000 36.73%
2023 -14.676.000 -69.26%
2023 -15.139.000 3.06%
2024 -5.720.000 -164.67%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BIOLASE, Inc. Gross Profit
Year Gross Profit Growth
1992 2.100.000
1993 100.000 -2000%
1994 300.000 66.67%
1995 600.000 50%
1996 200.000 -200%
1997 400.000 50%
1998 200.000 -100%
1999 2.964.918 93.25%
2000 4.994.257 40.63%
2001 10.588.000 52.83%
2002 18.097.000 41.49%
2003 31.551.000 42.64%
2004 36.009.000 12.38%
2005 30.806.000 -16.89%
2006 36.489.000 15.57%
2007 34.525.000 -5.69%
2008 32.662.000 -5.7%
2009 20.062.000 -62.81%
2010 8.825.000 -127.33%
2011 21.318.000 58.6%
2012 26.478.000 19.49%
2013 21.530.000 -22.98%
2014 18.172.000 -18.48%
2015 15.950.000 -13.93%
2016 20.308.000 21.46%
2017 15.126.000 -34.26%
2018 16.895.000 10.47%
2019 14.288.000 -18.25%
2020 6.173.000 -131.46%
2021 16.529.000 62.65%
2022 15.911.000 -3.88%
2023 14.984.000 -6.19%
2023 16.724.001 10.4%
2024 18.436.000 9.29%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BIOLASE, Inc. Net Profit
Year Net Profit Growth
1992 -5.500.000
1993 -7.500.000 26.67%
1994 -3.100.000 -141.94%
1995 -2.000.000 -55%
1996 -2.500.000 20%
1997 -2.800.000 10.71%
1998 -10.300.000 72.82%
1999 -4.797.137 -114.71%
2000 -3.727.977 -28.68%
2001 -408.000 -813.72%
2002 2.630.000 115.51%
2003 19.058.000 86.2%
2004 -23.214.000 182.1%
2005 -17.510.000 -32.58%
2006 -4.689.000 -273.43%
2007 -7.280.000 35.59%
2008 -9.129.000 20.25%
2009 -2.956.000 -208.83%
2010 -12.021.000 75.41%
2011 -4.486.000 -167.97%
2012 -3.056.000 -46.79%
2013 -11.482.000 73.38%
2014 -18.926.000 39.33%
2015 -20.278.000 6.67%
2016 -15.371.000 -31.92%
2017 -16.851.000 8.78%
2018 -21.516.000 21.68%
2019 -17.855.000 -20.5%
2020 -16.829.000 -6.1%
2021 -16.158.000 -4.15%
2022 -28.634.000 43.57%
2023 -18.356.000 -55.99%
2023 -20.632.000 11.03%
2024 -11.192.000 -84.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BIOLASE, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 -14.628
1993 -10.965 -33.41%
1994 -3.974 -175.89%
1995 -1.919 -107.09%
1996 -2.339 17.92%
1997 -2.256 -3.63%
1998 -7.373 69.4%
1999 -2.998 -145.9%
2000 -2.097 -43.03%
2001 -226 -831.56%
2002 539 141.74%
2003 9.811 94.51%
2004 -10.797 190.86%
2005 -8.190 -31.85%
2006 -2.154 -280.35%
2007 -3.291 34.58%
2008 -4.072 19.16%
2009 -1.313 -210.29%
2010 -5.242 74.97%
2011 -1.722 -204.41%
2012 -1.115 -54.44%
2013 -4.112 72.88%
2014 -5.259 21.8%
2015 -4.356 -20.71%
2016 -3.167 -37.54%
2017 -2.856 -10.89%
2018 -2.613 -9.34%
2019 -1.924 -35.83%
2020 -688 -179.51%
2021 -273 -152.01%
2022 -413 33.9%
2023 -16 -2653.33%
2023 -16 6.25%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BIOLASE, Inc. Free Cashflow
Year Free Cashflow Growth
1992 -6.200.000
1993 -6.100.000 -1.64%
1994 -2.700.000 -125.93%
1995 -1.700.000 -58.82%
1996 -2.300.000 26.09%
1997 -4.100.000 43.9%
1998 -5.100.000 19.61%
1999 -1.965.255 -159.51%
2000 -4.847.302 59.46%
2001 -1.191.000 -306.99%
2002 157.000 858.6%
2003 5.873.000 97.33%
2004 -3.002.000 295.64%
2005 -18.915.000 84.13%
2006 -1.900.000 -895.53%
2007 -4.144.000 54.15%
2008 -5.501.000 24.67%
2009 -3.020.000 -82.15%
2010 -4.049.000 25.41%
2011 -13.748.000 70.55%
2012 -2.486.000 -453.02%
2013 -9.981.000 75.09%
2014 -16.399.000 39.14%
2015 -19.575.000 16.22%
2016 -12.061.000 -62.3%
2017 -19.159.000 37.05%
2018 -14.705.000 -30.29%
2019 -12.953.000 -13.53%
2020 -12.891.000 -0.48%
2021 -17.417.000 25.99%
2022 -30.488.000 42.87%
2023 -15.402.000 -97.95%
2023 -2.770.000 -456.03%
2024 -761.000 -263.99%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BIOLASE, Inc. Operating Cashflow
Year Operating Cashflow Growth
1992 -5.400.000
1993 -5.800.000 6.9%
1994 -2.600.000 -123.08%
1995 -1.700.000 -52.94%
1996 -2.200.000 22.73%
1997 -4.000.000 45%
1998 -4.800.000 16.67%
1999 -1.897.337 -152.99%
2000 -3.778.430 49.79%
2001 -1.037.000 -264.36%
2002 635.000 263.31%
2003 6.328.000 89.97%
2004 -1.571.000 502.8%
2005 -17.051.000 90.79%
2006 425.000 4112%
2007 -3.269.000 113%
2008 -4.520.000 27.68%
2009 -2.571.000 -75.81%
2010 -3.812.000 32.56%
2011 -13.320.000 71.38%
2012 -1.664.000 -700.48%
2013 -9.296.000 82.1%
2014 -16.201.000 42.62%
2015 -17.772.000 8.84%
2016 -10.647.000 -66.92%
2017 -18.412.000 42.17%
2018 -14.147.000 -30.15%
2019 -12.746.000 -10.99%
2020 -12.795.000 0.38%
2021 -16.710.000 23.43%
2022 -26.761.000 37.56%
2023 -14.091.000 -89.92%
2023 -2.588.000 -444.47%
2024 -734.000 -252.59%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BIOLASE, Inc. Capital Expenditure
Year Capital Expenditure Growth
1992 800.000
1993 300.000 -166.67%
1994 100.000 -200%
1995 0 0%
1996 100.000 100%
1997 100.000 0%
1998 300.000 66.67%
1999 67.918 -341.71%
2000 1.068.872 93.65%
2001 154.000 -594.07%
2002 478.000 67.78%
2003 455.000 -5.05%
2004 1.431.000 68.2%
2005 1.864.000 23.23%
2006 2.325.000 19.83%
2007 875.000 -165.71%
2008 981.000 10.81%
2009 449.000 -118.49%
2010 237.000 -89.45%
2011 428.000 44.63%
2012 822.000 47.93%
2013 685.000 -20%
2014 198.000 -245.96%
2015 1.803.000 89.02%
2016 1.414.000 -27.51%
2017 747.000 -89.29%
2018 558.000 -33.87%
2019 207.000 -169.57%
2020 96.000 -115.63%
2021 707.000 86.42%
2022 3.727.000 81.03%
2023 1.311.000 -184.29%
2023 182.000 -620.33%
2024 27.000 -574.07%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BIOLASE, Inc. Equity
Year Equity Growth
1992 2.800.000
1993 2.700.000 -3.7%
1994 1.700.000 -58.82%
1995 1.800.000 5.56%
1996 3.900.000 53.85%
1997 2.100.000 -85.71%
1998 700.000 -200%
1999 -939.272 174.53%
2000 1.056.871 188.87%
2001 1.579.000 33.07%
2002 5.187.000 69.56%
2003 31.782.000 83.68%
2004 33.978.000 6.46%
2005 21.294.000 -59.57%
2006 21.966.000 3.06%
2007 16.491.000 -33.2%
2008 9.390.000 -75.62%
2009 7.929.000 -18.43%
2010 -3.047.000 360.22%
2011 12.569.000 124.24%
2012 11.794.000 -6.57%
2013 8.481.000 -39.06%
2014 42.056.000 79.83%
2015 24.925.000 -68.73%
2016 22.065.000 -12.96%
2017 29.260.000 24.59%
2018 11.089.000 -163.87%
2019 377.000 -2841.38%
2020 10.028.000 96.24%
2021 25.208.000 60.22%
2022 4.889.000 -415.61%
2023 -247.000 2079.35%
2023 5.884.000 104.2%
2024 -4.329.000 235.92%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BIOLASE, Inc. Assets
Year Assets Growth
1992 5.600.000
1993 5.100.000 -9.8%
1994 2.400.000 -112.5%
1995 2.500.000 4%
1996 4.700.000 46.81%
1997 3.400.000 -38.24%
1998 3.900.000 12.82%
1999 2.672.313 -45.94%
2000 6.599.100 59.5%
2001 7.561.000 12.72%
2002 14.395.000 47.47%
2003 44.501.000 67.65%
2004 58.746.000 24.25%
2005 45.129.000 -30.17%
2006 48.578.000 7.1%
2007 44.308.000 -9.64%
2008 35.708.000 -24.08%
2009 22.177.000 -61.01%
2010 18.147.000 -22.21%
2011 29.807.000 39.12%
2012 31.973.000 6.77%
2013 31.038.000 -3.01%
2014 59.403.000 47.75%
2015 42.251.000 -40.6%
2016 41.941.000 -0.74%
2017 42.984.000 2.43%
2018 38.516.000 -11.6%
2019 31.847.000 -20.94%
2020 41.025.000 22.37%
2021 55.284.000 25.79%
2022 38.186.000 -44.78%
2023 35.101.000 -8.79%
2023 38.745.000 9.41%
2024 30.641.000 -26.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BIOLASE, Inc. Liabilities
Year Liabilities Growth
1992 2.800.000
1993 2.400.000 -16.67%
1994 700.000 -242.86%
1995 700.000 0%
1996 800.000 12.5%
1997 1.300.000 38.46%
1998 3.200.000 59.38%
1999 3.611.585 11.4%
2000 5.542.229 34.84%
2001 5.982.000 7.35%
2002 9.208.000 35.03%
2003 12.719.000 27.6%
2004 24.768.000 48.65%
2005 23.835.000 -3.91%
2006 26.612.000 10.44%
2007 27.817.000 4.33%
2008 26.318.000 -5.7%
2009 14.248.000 -84.71%
2010 21.194.000 32.77%
2011 17.238.000 -22.95%
2012 20.179.000 14.57%
2013 22.557.000 10.54%
2014 17.347.000 -30.03%
2015 17.326.000 -0.12%
2016 19.876.000 12.83%
2017 13.724.000 -44.83%
2018 27.427.000 49.96%
2019 31.470.000 12.85%
2020 30.997.000 -1.53%
2021 30.076.000 -3.06%
2022 33.297.000 9.67%
2023 35.348.000 5.8%
2023 32.861.000 -7.57%
2024 34.970.000 6.03%

BIOLASE, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.38
Net Income per Share
-0.57
Price to Earning Ratio
-0.03x
Price To Sales Ratio
0.02x
POCF Ratio
-0.06
PFCF Ratio
-0.06
Price to Book Ratio
-0.15
EV to Sales
0.22
EV Over EBITDA
-0.76
EV to Operating CashFlow
-0.88
EV to FreeCashFlow
-0.85
Earnings Yield
-28.75
FreeCashFlow Yield
-16.27
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
1.3
Graham NetNet
-0.62

Income Statement Metrics

Net Income per Share
-0.57
Income Quality
0.6
ROE
122.67
Return On Assets
-0.63
Return On Capital Employed
30.88
Net Income per EBT
1
EBT Per Ebit
1.16
Ebit per Revenue
-0.36
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.25
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.33
Operating Profit Margin
-0.36
Pretax Profit Margin
-0.42
Net Profit Margin
-0.42

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.35
Free CashFlow per Share
-0.36
Capex to Operating CashFlow
-0.03
Capex to Revenue
0.01
Capex to Depreciation
0.14
Return on Invested Capital
-1.6
Return on Tangible Assets
-0.69
Days Sales Outstanding
38.34
Days Payables Outstanding
64.9
Days of Inventory on Hand
128.88
Receivables Turnover
9.52
Payables Turnover
5.62
Inventory Turnover
2.83
Capex per Share
0.01

Balance Sheet

Cash per Share
0,16
Book Value per Share
-0,13
Tangible Book Value per Share
-0.22
Shareholders Equity per Share
-0.13
Interest Debt per Share
0.51
Debt to Equity
-3.38
Debt to Assets
0.48
Net Debt to EBITDA
-0.7
Current Ratio
0.71
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-792000
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0.1
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
11088500
Debt to Market Cap
20.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BIOLASE, Inc. Dividends
Year Dividends Growth
2004 0
2005 0 0%

BIOLASE, Inc. Profile

About BIOLASE, Inc.

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

CEO
Mr. John R. Beaver
Employee
157
Address
27042 Towne Centre Drive
Foothill Ranch, 92610-2811

BIOLASE, Inc. Executives & BODs

BIOLASE, Inc. Executives & BODs
# Name Age
1 Ms. Jennifer Bright
Chief Financial Officer
70
2 Mr. Steven Sandor
Chief Operating Officer
70
3 Mr. John R. Beaver
President, Chief Executive Officer & Director
70
4 Mr. Michael C. Carroll
Corporate Secretary
70

BIOLASE, Inc. Competitors